REVIEW OF CLINICAL TRIALS DURING THE COVID-19 PANDEMIC
DOI:
https://doi.org/10.15547/tjs.2024.04.007Keywords:
trial register, trial protocol, BulgariaAbstract
Objective: The systematic data on clinical trials during the COVID-19 pandemic are scarce. We aimed to review the dynamics of clinical trials in the new reality. Materials and methods: We collected data for all 112 clinical trials completed or prematurely ended in 2019-2021. The main data sources are the Register of Authorized Clinical Trials, the Bulgarian Drug Agency, and the European Union Clinical Trials Register of the European Union Drug Regulating Authorities Clinical Trials Databases. Results: General information of clinical trials is aligned with international trends, while the population of trial subjects is in line with the demographic situation in Bulgaria. The adaptability of trial sites to conduct multi-regional trials is the newest factor for clinical trials dynamics. Conclusions: The size of country’s population is not a factor in the dynamics of clinical trials. A therapeutic area of clinical trials in line with local trends and the adaptability of trial sites to the international trends of most common diseases are attractive factor for conducting clinical trials in Bulgaria.
References
World Health Organization. A healthy return: Investment case for a sustainably financed WHO. Geneva, 2022.
Paquettea M, Kelecevicc J, Schwartza L, Nieuwlaata R. Ethical issues in competing clinical trials. Contemporary Clinical Trials Communications, 14:1-4, 2019.
KPMG Bulgaria. Clinical trials in Bulgaria. Main challenges. Sofia, 2015.
Kirilov B, Antonov L, Grigorov E. Dynamics and sources of adverse drug reaction reports related to COVID-19 vaccines in Bulgaria. Social Medicine, 30(1):13-16, 2022.
European Commission. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. Brussels, 2022.
Gergova V, Serbezova A, Sidjimova D. Analysis on decentralized clinical trials in some European countries. Archives of the Balkan Medical Union, 56(4):394-401, 2021.
Committee for Medicinal Products for Human Use. ICH guideline E17 on general principles for planning and design of multi-regional clinical trials. EMA/CHMP/ICH/453276/2016. London, 2017.
Zaykova K, Nikolova S, Pancheva R, Serbezova A. A survey of knowledge, attitudes and practice of antibiotics among Bulgarian population. Biotechnology & Biotechnological equipment, 36(1):933–941, 2022.
World Health Organization. World health statistics 2022. Geneva, 2022.
European Medicines Agency. Choice of control group in clinical trials. CPMP/ICH/364/96. London, 2006.
OECD/European Observatory on Health Systems and Policies. Bulgaria: country health profile 2021, state of health in the EU. OECD Publishing, Paris/European Observatory on Health Systems and Policies. Brussels, 2021.
Savova A, Manova M, Tachkov K, Petrova G. The role of insurance policies in the drug pricing landscape. Expert Review of Pharmacoeconomics & Outcomes Research, 24(3):1-14, 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Trakia University
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
